Regulatory Telomir seeks FDA approval for Telomir-1 to treat breast cancer Pharmaceutical Business ReviewThe IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment.RegulatoryOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA points to liver injury with Amgen’s TavneosNext: Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
